drugset / Trial / NCT06279338

A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score

NCT06279338

NaSingle-groupOpen-labelTreatment

Summary

Figure out the Efficacy and Safety of Azacitidine Combined with BUCY2 Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome with Moderate High IPSS-M Score

Timeline

Start
2024-03-01
Primary completion
2026-01-31
Completion
2026-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2